{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T09:10:55Z","timestamp":1790500255644,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.clgc.2017.10.019","type":"journal-article","created":{"date-parts":[[2017,11,7]],"date-time":"2017-11-07T23:25:52Z","timestamp":1510097152000},"page":"e587-e593","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Intravesical Immunomodulatory Imiquimod Enhances Bacillus Calmette-Gu\u00e9rin Downregulation of Nonmuscle-invasive Bladder Cancer"],"prefix":"10.1016","volume":"16","author":[{"given":"Juliana A.","family":"Camargo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela R.","family":"Passos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen L.","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanase","family":"Billis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e1rio J.A.","family":"Saad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2092-414X","authenticated-orcid":false,"given":"Leonardo O.","family":"Reis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2017.10.019_bib1","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1177\/1756287211431976","article-title":"Best practice in the treatment of nonmuscle invasive bladder cancer","volume":"4","author":"Anastasiadis","year":"2012","journal-title":"Ther Adv Urol"},{"key":"10.1016\/j.clgc.2017.10.019_bib2","first-page":"9","article-title":"Cancer statistics, 2014","volume":"64","author":"Siegel","year":"2014","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clgc.2017.10.019_bib3","first-page":"682","article-title":"Intravesical bacillus Calmette-Gu\u00e9rin efficiently reduces p70S6K1 but not 4E-BP1 phosphorylation in nonmuscle invasive bladder cancer","volume":"193","author":"Ferrari","year":"2015","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.clgc.2017.10.019_bib4","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1158\/2326-6066.CIR-16-0267","article-title":"Intravesical BCG induces CD4+ T-cell expansion in an immune competent model of bladder cancer","volume":"5","author":"Kates","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.clgc.2017.10.019_bib5","first-page":"1915","article-title":"Toll-like receptors in normal and malignant human bladders","volume":"185","author":"Ayari","year":"2011","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.clgc.2017.10.019_bib6","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.urolonc.2016.09.006","article-title":"A\u00a0phase 2 study of TMX-101, intravesical imiquimod, for the treatment of carcinoma in situ bladder cancer","volume":"35","author":"Donin","year":"2017","journal-title":"Urol Oncol"},{"issue":"suppl 2","key":"10.1016\/j.clgc.2017.10.019_bib7","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1590\/S0102-86502011000800019","article-title":"Anatomical features of the urethra and urinary bladder catheterization in female mice and rats: an essential translational tool","volume":"26","author":"Reis","year":"2011","journal-title":"Acta Cir Bras"},{"key":"10.1016\/j.clgc.2017.10.019_bib8","first-page":"438","article-title":"Anti-angiogenic effects of the superantigen staphylococcal enterotoxin B and bacillus Calmette-Gu\u00e9rin immunotherapy for nonmuscle invasive bladder cancer","volume":"187","author":"Reis","year":"2012","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.clgc.2017.10.019_bib9","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1001\/archderm.142.12.1575","article-title":"Imiquimod in combination with meglumine antimoniate for cutaneous leishmaniasis: a randomized assessor-blind controlled trial","volume":"142","author":"Firooz","year":"2006","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clgc.2017.10.019_bib10","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1177\/106689690501300203","article-title":"The 2004 WHO classification of bladder tumors: a summary and commentary","volume":"13","author":"Montironi","year":"2005","journal-title":"Int J Surg Pathol"},{"key":"10.1016\/j.clgc.2017.10.019_bib11","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s00345-010-0545-3","article-title":"Evolution on experimental animal model for upper urothelium carcinogenesis","volume":"28","author":"Reis","year":"2010","journal-title":"World J Urol"},{"key":"10.1016\/j.clgc.2017.10.019_bib12","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.eururo.2013.06.003","article-title":"EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013","volume":"64","author":"Babjuk","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2017.10.019_bib13","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1158\/1078-0432.CCR-12-0408","article-title":"Molecular pathways: toll-like receptors in the tumor microenvironment\u2014poor prognosis or new therapeutic opportunity","volume":"19","author":"Ridnour","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clgc.2017.10.019_bib14","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/QCO.0b013e3282f88b5d","article-title":"Mycobacterial interaction with innate receptors: TLRs, C-type lectins, and NLRs","volume":"21","author":"Jo","year":"2008","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.clgc.2017.10.019_bib15","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/BF01741603","article-title":"Presence of activated lymphocytes in the urine of patients with superficial bladder cancer after intravesical immunotherapy with bacillus Calmette-Gu\u00e9rin","volume":"33","author":"De Boer","year":"1991","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.clgc.2017.10.019_bib16","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1016\/S0140-6736(98)07422-4","article-title":"BCG immunotherapy of bladder cancer: 20 years on","volume":"353","author":"Alexandroff","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.clgc.2017.10.019_bib17","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/jcmm.12718","article-title":"Imiquimod-induced apoptosis of melanoma cells is mediated by ER stress-dependent Noxa induction and enhanced by NF-\u03baB inhibition","volume":"20","author":"El-Khattouti","year":"2016","journal-title":"J\u00a0Cell Mol Med"},{"key":"10.1016\/j.clgc.2017.10.019_bib18","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/jid.2011.247","article-title":"Immunomodulation by imiquimod in patients with high-risk primary melanoma","volume":"132","author":"Narayan","year":"2012","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.clgc.2017.10.019_bib19","first-page":"371","article-title":"Treatment of in-transit melanoma with intralesional bacillus Calmette-Gu\u00e9rin (BCG) and topical imiquimod 5% cream: a report of 3 cases","volume":"38","author":"Kibbi","year":"2015","journal-title":"J\u00a0Immunother"},{"key":"10.1016\/j.clgc.2017.10.019_bib20","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s13555-015-0088-z","article-title":"Imiquimod 5% as adjuvant therapy for incompletely excised infiltrative nodular basal cell carcinoma and dermoscopy to monitor treatment response","volume":"5","author":"Rold\u00e1n-Mar\u00edn","year":"2015","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.clgc.2017.10.019_bib21","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.cell.2012.03.017","article-title":"mTOR signaling in growth control and disease","volume":"149","author":"Laplante","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.clgc.2017.10.019_bib22","doi-asserted-by":"crossref","first-page":"11541","DOI":"10.1007\/s13277-016-5083-1","article-title":"mTOR inhibitors in urinary bladder cancer","volume":"37","author":"Pinto-Leite","year":"2016","journal-title":"Tumour Biol"},{"key":"10.1016\/j.clgc.2017.10.019_bib23","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s11882-009-0050-1","article-title":"Autophagy in immune cell regulation and dysregulation","volume":"9","author":"Chaturvedi","year":"2009","journal-title":"Curr Allergy Asthma Rep"},{"key":"10.1016\/j.clgc.2017.10.019_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.lfs.2015.03.001","article-title":"The S6K protein family in health and disease","volume":"131","author":"Tavares","year":"2015","journal-title":"Life Sci"},{"key":"10.1016\/j.clgc.2017.10.019_bib25","first-page":"964","article-title":"Immune mechanisms in bacillus Calmette-Gu\u00e9rin immunotherapy for superficial bladder cancer","volume":"170","author":"B\u00f6hle","year":"2003","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.clgc.2017.10.019_bib26","first-page":"e860","article-title":"Intravesical thalidomide boosts bacillus Calmette-Gu\u00e9rin (BCG) in non-muscle invasive bladder cancer treatment","volume":"197","author":"Passos","year":"2017","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.clgc.2017.10.019_bib27","first-page":"2347","article-title":"Antitumor effects of imidazoquinolines in urothelial cell carcinoma of the bladder","volume":"177","author":"Smith","year":"2007","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.clgc.2017.10.019_bib28","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nrurol.2014.15","article-title":"The mechanism of action of BCG therapy for bladder cancer\u2014a current perspective","volume":"11","author":"Redelman-Sidi","year":"2014","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.clgc.2017.10.019_bib29","doi-asserted-by":"crossref","first-page":"21176","DOI":"10.1074\/jbc.270.36.21176","article-title":"Eukaryotic translation initiation factor 4E regulates expression of cyclin D1 at transcriptional and post-transcriptional levels","volume":"270","author":"Rosenwald","year":"1995","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.clgc.2017.10.019_bib30","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1038\/labinvest.2010.133","article-title":"Expanding therapeutic targets in bladder cancer: the PI3K\/Akt\/mTOR pathway","volume":"90","author":"Ching","year":"2010","journal-title":"Lab Invest"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155876731730335X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155876731730335X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:30:38Z","timestamp":1761564638000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S155876731730335X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["S155876731730335X"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2017.10.019","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intravesical Immunomodulatory Imiquimod Enhances Bacillus Calmette-Gu\u00e9rin Downregulation of Nonmuscle-invasive Bladder Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2017.10.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}